文献速递流行病学与生物统计真实世界研究与卫生经济新药、器械与细胞基因治疗研发

利用共享数据更新罗格列酮心血管风险认知:个体患者与汇总水平Meta分析

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
PubMed 文献 · BMJ · 2020-02-05

结果显示罗格列酮与复合心血管事件风险增加33%相关(OR 1.33,95%CI 1.09-1.61),其中心力衰竭风险增加最为显著(OR 1.54,95%CI 1.14-2.09)。仅用汇总数据时心肌梗死风险估计被削弱。

要点

  • 罗格列酮与复合心血管事件风险增加33%相关(OR 1.33,95%CI 1.09-1.61)
  • 心力衰竭风险显著增加(OR 1.54,95%CI 1.14-2.09)
  • 安全性Meta分析应优先获取个体患者数据以减少事件漏报

核心结论

  • 罗格列酮与心血管风险增加相关,中心力衰竭事件风险最为显著。
  • 心肌梗死风险在各项分析中均升高,但仅用汇总数据时效应估计被削弱。
  • 因IPD报告更多心肌梗死和更少心血管死亡,安全性Meta分析可能需要共享IPD。

研究设计与样本

  • 系统综述与随机对照试验Meta分析,检索至2019年1月。
  • 从GSK研究注册平台、MEDLINE、PubMed、Embase、Web of Science、Cochrane CENTRAL、Scopus和ClinicalTrials.gov获取汇总数据。
  • 纳入比较罗格列酮与任何对照、疗程至少24周的成人II-IV期随机对照试验。

主要发现

  • 复合事件OR 1.33(95%CI 1.09-1.61),采用0.5连续性校正和随机效应模型。
  • 心肌梗死OR 1.17(0.92-1.51),心力衰竭OR 1.54(1.14-2.09),心血管死亡OR 1.15(0.55-2.41),非心血管死亡OR 1.18(0.60-2.30)。
  • 含无IPD试验的分析中,心肌梗死OR减弱至1.09(0.88-1.35),心血管死亡OR为1.12(0.72-1.74)。
  • 29项可用IPD并曾纳入汇总数据Meta分析的试验中,26项通过IPD识别出更多心肌梗死事件,5项识别出更少心血管死亡。

临床怎么用

  • 评估罗格列酮安全性时应关注心力衰竭风险。
  • 开展药物安全性Meta分析时,若条件允许应优先使用个体患者数据。
  • 仅依赖汇总数据可能低估心肌梗死等不良事件风险。

局限性

  • 部分试验无个体患者数据,仅能使用汇总数据分析心肌梗死和心血管死亡。
  • 不同连续性校正方法和零事件处理可能影响效应估计。
  • 研究仅纳入至少24周的II-IV期随机对照试验,未涵盖观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To conduct a systematic review and meta-analysis of the effects of rosiglitazone treatment on cardiovascular risk and mortality using multiple data sources and varying analytical approaches with three aims in mind: to clarify uncertainties about the cardiovascular risk of rosiglitazone; to determine whether different analytical approaches are likely to alter the conclusions of adverse event meta-analyses; and to inform efforts to promote clinical trial transparency and data sharing. DESIGN: Systematic review and meta-analysis of randomized controlled trials. DATA SOURCES: GlaxoSmithKline's (GSK's) ClinicalStudyDataRequest.com for individual patient level data (IPD) and GSK's Study Register platforms, MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Registry of Controlled Trials, Scopus, and ClinicalTrials.gov from inception to January 2019 for summary level data. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomized, controlled, phase II-IV clinical trials that compared rosiglitazone with any control for at least 24 weeks in adults. DATA EXTRACTION AND SYNTHESIS: For analyses of trials for which IPD were available, a composite outcome of acute myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular related death was examined. These four events were examined independently as secondary analyses. For analyses including trials for which IPD were not available, myocardial infarction and cardiovascular related death were examined, which were determined from summary level data. Multiple meta-analyses were conducted that accounted for trials with zero events in one or both arms with two different continuity corrections (0.5 constant and treatment arm) to calculate odds ratios and risk ratios with 95% confidence intervals. RESULTS: 33 eligible trials were identified from ClinicalStudyDataRequest.com for which IPD were available (21 156 patients). Additionally, 103 trials for which IPD were not available were included in the meta-analyses for myocardial infarction (23 683 patients), and 103 trials for which IPD were not available contributed to the meta-analyses for cardiovascular related death (22 772 patients). Among 29 trials for which IPD were available and that were included in previous meta-analyses using GSK's summary level data, more myocardial infarction events were identified by using IPD instead of summary level data for 26 trials, and fewer cardiovascular related deaths for five trials. When analyses were limited to trials for which IPD were available, and a constant continuity correction of 0.5 and a random effects model were used to account for trials with zero events in only one arm, patients treated with rosiglitazone had a 33% increased risk of a composite event compared with controls (odds ratio 1.33, 95% confidence interval 1.09 to 1.61; rosiglitazone population: 274 events among 11 837 patients; control population: 219 events among 9319 patients). The odds ratios for myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular related death were 1.17 (0.92 to 1.51), 1.54 (1.14 to 2.09), 1.15 (0.55 to 2.41), and 1.18 (0.60 to 2.30), respectively. For analyses including trials for which IPD were not available, odds ratios for myocardial infarction and cardiovascular related death were attenuated (1.09, 0.88 to 1.35, and 1.12, 0.72 to 1.74, respectively). Results were broadly consistent when analyses were repeated using trials with zero events across both arms and either of the two continuity corrections was used. CONCLUSIONS: The results suggest that rosiglitazone is associated with an increased cardiovascular risk, especially for heart failure events. Although increased risk of myocardial infarction was observed across analyses, the strength of the evidence varied and effect estimates were attenuated when summary level data were used in addition to IPD. Because more myocardial infarctions and fewer cardiovascular related deaths were reported in the IPD than in the summary level data, sharing IPD might be necessary when performing meta-analyses focused on safety. SYSTEMATIC REVIEW REGISTRATION: OSF Home https://osf.io/4yvp2/.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Wallach JD, Wang K, Zhang AD, et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. 2020. PMID: 32024657. doi:10.1136/bmj.l7078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。